ANI Pharmaceuticals (ANIP) said Wednesday that the US Food and Drug Administration has approved its 10 mg and 20 mg isosorbide mononitrate tablet, a generic version of the reference listed drug Monoket.
The company said it launched the product after receiving the FDA approval.
Shares of the company were up 7.1% in premarket activity Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.